Roger Klein Sells 9,000 Shares of Evoke Pharma (NASDAQ:EVOK) Stock

Evoke Pharma, Inc. (NASDAQ:EVOK) major shareholder Roger Klein sold 9,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the sale, the insider directly owned 29,000 shares in the company, valued at approximately $308,850. This represents a 23.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Evoke Pharma Stock Up 0.6%

Evoke Pharma stock opened at $10.69 on Friday. Evoke Pharma, Inc. has a twelve month low of $1.94 and a twelve month high of $10.79. The company has a market capitalization of $16.68 million, a P/E ratio of -4.18 and a beta of -0.14. The stock’s 50 day moving average is $5.39 and its 200 day moving average is $4.42.

Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.32). Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.The company had revenue of $3.75 million during the quarter, compared to the consensus estimate of $3.80 million.

Institutional Trading of Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. National Wealth Management Group LLC purchased a new position in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned 5.14% of Evoke Pharma as of its most recent SEC filing.

Analyst Ratings Changes

Several brokerages recently commented on EVOK. Laidlaw downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Thursday. Wall Street Zen upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Sunday, September 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evoke Pharma in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.